Literature DB >> 1747960

Inhibition of immune reactions in vivo by liposome associated transforming growth factor (TGF) type beta 1.

G Strassmann1, D R Bertolini, O Eidelman.   

Abstract

In view of its potent inhibitory capacity on immune cells in culture, we wished to determine the ability of transforming growth factor (TGF) beta 1 to down-regulate immune responses in vivo. Preliminary experiments suggested that, at the doses used, systemic injection of soluble TGF beta 1 could not affect bacterial-induced spleen enlargement in mice. Therefore, we sought to utilize a physiochemical property of this molecule, namely its high pI, to determine possible association between the ligand and preformed liposomes possessing an opposite charge. TGF beta 1 was preferentially associated with negatively charged, but not with neutral, liposomes. These TGF beta 1 associated liposomes were able to deliver a suppressive signal to indicator cells in vitro. Intravenous injection of TGF beta 1, associated with liposomes possessing an opposite charge, into mice immunized with heat-killed Corynebacterium parvum significantly reduced the size of the spleen as well as the number of splenocytes. Systemically administered TGF beta 1 associated liposomes could also inhibit delayed type hypersensitivity reactions to Listeria monocytogenes. These data suggest that appropriately administered, TGF beta 1 can inhibit immune responses in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1747960      PMCID: PMC1554192          DOI: 10.1111/j.1365-2249.1991.tb02965.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

Review 1.  The transforming growth factor-betas. A new family of immunoregulatory molecules.

Authors:  M A Palladino; R E Morris; H F Starnes; A D Levinson
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

2.  Human transforming growth factor beta.alpha 2-macroglobulin complex is a latent form of transforming growth factor beta.

Authors:  S S Huang; P O'Grady; J S Huang
Journal:  J Biol Chem       Date:  1988-01-25       Impact factor: 5.157

3.  Inflammatory and immunomodulatory roles of TGF-beta.

Authors:  S M Wahl; N McCartney-Francis; S E Mergenhagen
Journal:  Immunol Today       Date:  1989-08

4.  An improved method of purification of transforming growth factor, type beta from platelets.

Authors:  J L Cone; D R Brown; J E DeLarco
Journal:  Anal Biochem       Date:  1988-01       Impact factor: 3.365

Review 5.  Peptide growth factors are multifunctional.

Authors:  M B Sporn; A B Roberts
Journal:  Nature       Date:  1988-03-17       Impact factor: 49.962

Review 6.  Liposomes as drug carriers in cancer chemotherapy.

Authors:  J N Weinstein; L D Leserman
Journal:  Pharmacol Ther       Date:  1984       Impact factor: 12.310

7.  Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization.

Authors:  R K Assoian; A Komoriya; C A Meyers; D M Miller; M B Sporn
Journal:  J Biol Chem       Date:  1983-06-10       Impact factor: 5.157

8.  Cartilage-inducing factor-B is a unique protein structurally and functionally related to transforming growth factor-beta.

Authors:  S M Seyedin; P R Segarini; D M Rosen; A Y Thompson; H Bentz; J Graycar
Journal:  J Biol Chem       Date:  1987-02-15       Impact factor: 5.157

9.  Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness.

Authors:  A H Rook; J H Kehrl; L M Wakefield; A B Roberts; M B Sporn; D B Burlington; H C Lane; A S Fauci
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

10.  Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.

Authors:  J H Kehrl; A B Roberts; L M Wakefield; S Jakowlew; M B Sporn; A S Fauci
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

View more
  2 in total

1.  A distinct basic fibroblast growth factor (FGF-2)/FGF receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells.

Authors:  M Rusnati; P Dell'Era; C Urbinati; E Tanghetti; M L Massardi; Y Nagamine; E Monti; M Presta
Journal:  Mol Biol Cell       Date:  1996-03       Impact factor: 4.138

Review 2.  TGF-β Sustains Tumor Progression through Biochemical and Mechanical Signal Transduction.

Authors:  Robert L Furler; Douglas F Nixon; Christine A Brantner; Anastas Popratiloff; Christel H Uittenbogaart
Journal:  Cancers (Basel)       Date:  2018-06-14       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.